XL-protein is a company that develops and commercializes its proprietary PASylation technology to extend the plasma half-life of biopharmaceuticals. It provides a way to attach a solvated biopolymer with large hydrodynamic volume to a therapeutic protein or peptide. This polypeptide adopts a bulky random coil structure, which increases the size of the biopharmaceutical.